Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Bertone

Physician Assistant Johnston, RI Physician Assistant

NPI 1588112437 CMS profile 11051339

1526 Atwood Ave Ste 200, Johnston, RI 02919

Open in the dashboard

General payments

$7,289

385 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Bertone of Johnston, RI is reported in the CMS Open Payments database as having received $7,289 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2024 General $5,228 291
2023 General $1,753 80
2022 General $31 2
2021 General $257 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Bertone
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brittany Bertone were reported at $20. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brittany Bertone Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $257 $132 $37–$438 $132
2022 $31 $155 $48–$522 $149
2023 $1,753 $167 $52–$557 $160
2024 $5,228 $178 $55–$600 $164
2025 $20 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,195 59 payments
  2. Lundbeck LLC $628 31 payments
  3. Teva Pharmaceuticals USA, Inc. $553 40 payments
  4. Pfizer Inc. $551 28 payments
  5. Genentech USA, Inc. $315 15 payments
  6. Xeris Pharmaceuticals, Inc. $265 17 payments
  7. Biogen, Inc. $257 18 payments
  8. SK Life Science, Inc. $248 16 payments
  9. Novartis Pharmaceuticals Corporation $244 24 payments
  10. US WorldMeds, LLC $236 7 payments
  11. Other $2,797 130 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,099 381 payments
  2. Education $190 4 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $940 47 payments
  2. UBRELVY $884 44 payments
  3. NURTEC ODT $551 28 payments
  4. VYEPTI $487 21 payments
  5. ZAVZPRET $358 20 payments
  6. Austedo XR $338 37 payments
  7. Enspryng $315 15 payments
  8. OCREVUS $315 15 payments
  9. KEVEYIS $265 17 payments
  10. INGREZZA $221 9 payments
  11. Other $4,060 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,566

Median for Physician Assistant: 241

Drug cost

$295,674

Median for Physician Assistant: $4,110

Branded share of claims

29.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qulipta Atogepant Brand 65 $74,788
Nurtec Odt Rimegepant Sulfate Brand 25 $48,777
Xcopri Cenobamate Brand 46 $44,866
Gocovri Amantadine Hcl Brand 12 $33,659
Ajovy Autoinjector Fremanezumab-Vfrm Brand 27 $19,528
Emgality Pen Galcanezumab-Gnlm Brand 21 $14,728
Fycompa Perampanel Brand 12 $10,932
Aimovig Autoinjector Erenumab-Aooe Brand 15 $10,648
Lamotrigine Er Lamotrigine Brand 27 $7,590
Lacosamide Generic 66 $5,061

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$385 65 —
VYEPTI
$334 — —
UBRELVY
$329 — —
Austedo XR
$234 — —
REXULTI
$226 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record